Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chlorhexidine gluconate (CHG) foam improves adherence, satisfaction, and maintains central line associated infection rates compared to CHG wipes in pediatric hematology-oncology and bone marrow transplant patients.
Prudowsky ZD, Bledsaw K, Staton S, Zobeck M, DeJean J, Johnson-Bishop L, George A, Steffin D, Stevens A. Prudowsky ZD, et al. Pediatr Hematol Oncol. 2023 Mar;40(2):159-171. doi: 10.1080/08880018.2022.2090644. Epub 2022 Jul 15. Pediatr Hematol Oncol. 2023. PMID: 35838063
A Novel Oncodental Collaborative Team: Integrating Expertise for Central Line-Associated Bloodstream Infection Prevention in Pediatric Oncology Patients.
Bledsaw K, Prudowsky ZD, Yang E, Harriehausen CX, Robins J, DeJean J, Staton S, Campbell JR, Davis AL, George A, Steffin D, Stevens AM. Bledsaw K, et al. Among authors: stevens am. JCO Oncol Pract. 2023 Jan;19(1):e25-e32. doi: 10.1200/OP.22.00302. Epub 2022 Sep 22. JCO Oncol Pract. 2023. PMID: 36137251
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.
Schafer ES, Chao K, Stevens AM, Jo E, Hilsenbeck SG, Gossai NP, Doan A, Colace SI, Guinipero T, Otterson D, Kaplan JA, Hinson A, Pommert L, Wayne AS, Bhojwani D, Burke MJ. Schafer ES, et al. Among authors: stevens am. Pediatr Blood Cancer. 2022 Oct;69(10):e29812. doi: 10.1002/pbc.29812. Epub 2022 Jun 21. Pediatr Blood Cancer. 2022. PMID: 35726868 Clinical Trial.
Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Stevens AM, Xiang M, Heppler LN, Tošić I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terrell MC, Rashid R, Krueger MJ, Mangubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA. Stevens AM, et al. Blood Adv. 2019 Dec 23;3(24):4215-4227. doi: 10.1182/bloodadvances.2019000499. Blood Adv. 2019. PMID: 31856268 Free PMC article.
Defining the transcriptional control of pediatric AML highlights RARA as a superenhancer-regulated druggable dependency.
Perez MW, Sias-Garcia O, Daramola A, Wei H, Terrell M, Rashid R, Park WD, Duong K, Horton TM, Li F, Cherayil N, Koren JV, Gant VU, Junco JJ, Curry CV, Stevens AM, Lin CY, Yi JS. Perez MW, et al. Among authors: stevens am. Blood Adv. 2021 Dec 14;5(23):4864-4876. doi: 10.1182/bloodadvances.2020003737. Blood Adv. 2021. PMID: 34543389 Free PMC article.
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience.
Trabal A, Gibson A, He J, McCall D, Roth M, Nuñez C, Garcia M, Buzbee M, Toepfer L, Bidikian A, Daver N, Kadia T, Short NJ, Issa GC, Ravandi F, DiNardo CD, Montalban Bravo G, Garces S, Marcogliese A, Paek H, Dreyer Z, Brackett J, Redell M, Yi J, Garcia-Manero G, Konopleva M, Stevens A, Cuglievan B. Trabal A, et al. Cancers (Basel). 2023 Mar 26;15(7):1983. doi: 10.3390/cancers15071983. Cancers (Basel). 2023. PMID: 37046645 Free PMC article.
265 results